• Mitsubishi Tanabe Pharma America Presents Positive Results from Pivotal Phase 3 BouNDless Trial of Investigational ND0612 in People with Parkinson’s Disease Experiencing Motor Fluctuations
  

  ---

• Mitsubishi Tanabe Pharma America Announces Presentations in Parkinson’s Disease at 2023 International Congress of Parkinson’s Disease and Movement Disorders Society (MDS)
  

  ---

• Mitsubishi Tanabe Pharma America Announces Post-Hoc Analysis Examining Effect of Early Intervention with RADICAVA^® (edaravone) on Survival and Disease Progression Milestones in People with ALS
  

  ---

• Mitsubishi Tanabe Pharma America Announces Update on Global, Phase 3b MT-1186-A02 Postmarketing Study of Oral Edaravone in ALS
  

  ---

• Mitsubishi Tanabe Pharma America to Share Details from Phase 3b RADICAVA ORS^® (edaravone) Study at European Network to Cure ALS (ENCALS) Meeting 2023
  

  ---

• Mitsubishi Tanabe Pharma America Highlights Latest Research in Parkinson’s Disease at EAN and WPC 2023 Congresses
  

  ---

• Mitsubishi Tanabe Pharma America Celebrates One-Year Anniversary of RADICAVA ORS® (edaravone) Launch in the U.S.
  

  ---

• Mitsubishi Tanabe Pharma America to Partner with ALS/MND Natural History Study Consortium to Collect Real-World Data in ALS with the Goal of Improving Patient Care
  

  ---

• Mitsubishi Tanabe Pharma America Announces Presentations at XXVIII World Congress on Parkinson’s Disease and Related Disorders
  

  ---

• Mitsubishi Tanabe Pharma America to Present Latest Findings Across ALS and Parkinson’s Disease at 2023 American Academy of Neurology Annual Meeting
  

  ---